185 related articles for article (PubMed ID: 32073954)
1. Geographic and Ethnic Heterogeneity of Germline
Golan T; Kindler HL; Park JO; Reni M; Macarulla T; Hammel P; Van Cutsem E; Arnold D; Hochhauser D; McGuinness D; Locker GY; Goranova T; Schatz P; Liu YZ; Hall MJ
J Clin Oncol; 2020 May; 38(13):1442-1454. PubMed ID: 32073954
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic testing.
Paiella S; Azzolina D; Gregori D; Malleo G; Golan T; Simeone DM; Davis MB; Vacca PG; Crovetto A; Bassi C; Salvia R; Biankin AV; Casolino R
ESMO Open; 2023 Apr; 8(2):100881. PubMed ID: 36822114
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
Lucas AL; Frado LE; Hwang C; Kumar S; Khanna LG; Levinson EJ; Chabot JA; Chung WK; Frucht H
Cancer; 2014 Jul; 120(13):1960-7. PubMed ID: 24737347
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.
O'Shaughnessy J; Brezden-Masley C; Cazzaniga M; Dalvi T; Walker G; Bennett J; Ohsumi S
Breast Cancer Res; 2020 Oct; 22(1):114. PubMed ID: 33109210
[TBL] [Abstract][Full Text] [Related]
5. The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients.
Wu X; Wu L; Kong B; Liu J; Yin R; Wen H; Li N; Bu H; Feng Y; Li Q; Lu X; Wei J; Zhu X; Mills J; Ellison G; Gutjahr T; Liu Y
Int J Gynecol Cancer; 2017 Oct; 27(8):1650-1657. PubMed ID: 28692638
[TBL] [Abstract][Full Text] [Related]
6. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
7. Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999.
Chodick G; Struewing JP; Ron E; Rutter JL; Iscovich J
Eur J Med Genet; 2008; 51(2):141-7. PubMed ID: 18158280
[TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
9. Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
Hodgson D; Lai Z; Dearden S; Barrett JC; Harrington EA; Timms K; Lanchbury J; Wu W; Allen A; Senkus E; Domchek SM; Robson M
Ann Oncol; 2021 Dec; 32(12):1582-1589. PubMed ID: 34500047
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.
Stadler ZK; Salo-Mullen E; Patil SM; Pietanza MC; Vijai J; Saloustros E; Hansen NA; Kauff ND; Kurtz RC; Kelsen DP; Offit K; Robson ME
Cancer; 2012 Jan; 118(2):493-9. PubMed ID: 21598239
[TBL] [Abstract][Full Text] [Related]
11. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
12. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
[TBL] [Abstract][Full Text] [Related]
13. Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel.
Laitman Y; Simeonov M; Herskovitz L; Kushnir A; Shimon-Paluch S; Kaufman B; Zidan J; Friedman E
Breast Cancer Res Treat; 2012 Jun; 133(3):1153-7. PubMed ID: 22399190
[TBL] [Abstract][Full Text] [Related]
14. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
[TBL] [Abstract][Full Text] [Related]
15. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D
Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic acinar cell carcinoma is associated with
Kryklyva V; Haj Mohammad N; Morsink FHM; Ligtenberg MJL; Offerhaus GJA; Nagtegaal ID; de Leng WWJ; Brosens LAA
Cancer Biol Ther; 2019; 20(7):949-955. PubMed ID: 31002019
[TBL] [Abstract][Full Text] [Related]
17. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.
Holter S; Borgida A; Dodd A; Grant R; Semotiuk K; Hedley D; Dhani N; Narod S; Akbari M; Moore M; Gallinger S
J Clin Oncol; 2015 Oct; 33(28):3124-9. PubMed ID: 25940717
[TBL] [Abstract][Full Text] [Related]
18. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.
Lal G; Liu G; Schmocker B; Kaurah P; Ozcelik H; Narod SA; Redston M; Gallinger S
Cancer Res; 2000 Jan; 60(2):409-16. PubMed ID: 10667595
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
[TBL] [Abstract][Full Text] [Related]
20. The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.
Barnes-Kedar I; Bernstein-Molho R; Ginzach N; Hartmajer S; Shapira T; Magal N; Kalis ML; Peretz T; Shohat M; Basel-Salmon L; Friedman E; Bazak L; Goldberg Y
Breast Cancer Res Treat; 2018 Nov; 172(1):151-157. PubMed ID: 30014164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
